Welcome to our dedicated page for The Oncology Institute news (Ticker: TOI), a resource for investors and traders seeking the latest updates and insights on The Oncology Institute stock.
The Oncology Institute, Inc. (NASDAQ: TOI) is a leading cancer treatment and research organization focused on providing high-quality, value-based oncology care. Founded in 2007, TOI has established itself as a premier provider of comprehensive cancer treatment with over 70 clinic locations and a team exceeding 110 clinicians. The Institute offers a wide range of services, including infusion centers, outpatient blood transfusions, stem cell transplants, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling.
TOI operates in three primary segments: dispensary services, patient services, and clinical trials. The core of its operations lies in patient services, where personalized care plans are developed in collaboration with patients and their families to meet their unique needs. TOI’s mission is to advance oncology by making cutting-edge, evidence-based cancer care accessible within the community setting.
In recent developments, TOI announced a strategic partnership with WellBe Senior Medical to extend its High-Value Cancer Care Program to eligible patients in Illinois and Ohio. This initiative aims to enhance patient satisfaction, reduce acute care facility utilization, and support patients throughout their cancer treatment journey. Furthermore, TOI has joined Carrum Health’s Centers of Excellence network, providing high-value oncology care to non-metastatic breast cancer patients in Las Vegas.
TOI’s commitment to innovation in oncology care is also highlighted through its strategic collaboration with Healthly, a growing healthcare company focused on preventive medicine. Starting July 2024, TOI will offer its specialized cancer care services to Healthly’s affiliated patients and physicians across Southern California. This collaboration underscores TOI’s dedication to providing accessible and comprehensive cancer care in community settings.
Financially, TOI has a strong foundation supported by revenue generated predominantly from patient services. The Institute continues to expand its influence through partnerships and value-based care agreements, ensuring a sustainable and impactful presence in the oncology landscape. For more information, please visit theoncologyinstitute.com.
The Oncology Institute (NASDAQ: TOI) has announced that its executives will participate in multiple panel presentations at the APG 2024 Spring Conference in San Diego. Dr. Yale Podnos, Chief Medical Officer, will discuss the use of artificial intelligence in oncology practices during the breakout session titled 'AI on the Front Lines: Improving Outcomes and Reducing Costs for Complex Patients'. Additionally, CEO Dr. Daniel Virnich will join a panel discussing global risk management in pharmaceuticals. The event takes place in May 2024 and highlights the institute's focus on integrating advanced technology and risk management strategies in oncology.
The Oncology Institute (NASDAQ: TOI) announced its Q1 2024 financial results, reporting a 24.2% increase in consolidated revenue to $95 million. Despite this, the gross profit decreased by 15.1% to $12 million, with net losses reducing to $19.9 million from the previous year's $30 million. The net loss per share improved to $(0.22) from $(0.33). Adjusted EBITDA was $(10.9) million, higher than the $(7.4) million from the prior year. The company ended Q1 with $66 million in cash and short-term investments. Operationally, TOI signed seven new capitation and value-based contracts across three states, integrated a capitated risk contract with a health plan in Florida, and expanded its MSO model in Florida. The firm also increased the number of scripts dispensed by 70% and hired seven new providers, bringing the total to 126 employed providers across 73 clinics. CEO Daniel Virnich highlighted the company's revenue growth and new partnerships as key milestones.
The Oncology Institute, Inc. (NASDAQ: TOI) disclosed that Dr. Daniel Virnich, TOI’s CEO, will join the 'Defining the Next Chapter in Value-Based Care' panel at the Leerink Healthcare Transformation Summit on May 16, 2024. TOI is a leading value-based oncology practice in the U.S.
FAQ
What is the current stock price of The Oncology Institute (TOI)?
What is the market cap of The Oncology Institute (TOI)?
What services does The Oncology Institute, Inc. provide?
Where are The Oncology Institute's clinics located?
What recent partnerships has TOI announced?
How does TOI contribute to cancer research?
What is the focus of TOI's value-based care model?
How can patients access TOI's services?
What makes TOI's High-Value Cancer Care Program unique?
Who are the primary beneficiaries of TOI's services?
What role do clinical trials play at TOI?
How does TOI support patients financially?
